Abstracts Archive - Page 2309 of 2607 - ACR Meeting Abstracts

Abstract Number: 1850 • 2013 ACR/ARHP Annual Meeting
The Bromodomain Protein Inhibitor I-BET151 Suppresses Inflammatory and Matrix Degrading Properties Of Rheumatoid Arthritis Synovial Fibroblasts
Kerstin Klein¹, Renate E. Gay², Christoph Kolling³, Lih-Ling Lin⁴, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ³Schultess Clinic, Zurich, Switzerland, ⁴Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA
Background/Purpose: Bromodomain proteins (BRD) contain conserved acetyl-lysine binding domains that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks.…
Abstract Number: 1851 • 2013 ACR/ARHP Annual Meeting
Adenosine 2A Receptor Promotes Collagen Production By Human Fibroblasts Via Smad2/3-Independent Pathways Involving Cyclic AMP and AKT
Miguel Perez-Aso¹, Patricia Fernandez², Aranzazu Mediero³, Edwin SL Chan⁴ and Bruce N. Cronstein⁵, ¹Department of Translational Medicine, New York University School of Medicine, New York, NY, ²Medicine, National Cancer Institute, NIH, Bethesda, MD, ³Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Activation of Adenosine 2A Receptors (A2AR) promotes fibrosis and collagen synthesis. However, the underlying mechanism by which A2AR stimulate collagen synthesis is still unclear. …
Abstract Number: 1852 • 2013 ACR/ARHP Annual Meeting
Adenosine A2A Receptors (A2AR) Promote Scarring By Repressing Mir-29a
Ross C. Radusky¹, Miguel Perez-Aso², Andrew G. Franks Jr.³, Bruce N. Cronstein⁴ and Edwin SL Chan¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Translational Medicine, New York University School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: We have previously demonstrated that the nucleoside adenosine stimulates collagen production and induces dermal fibrosis in vitro and in vivo. Recent studies have demonstrated…
Abstract Number: 1853 • 2013 ACR/ARHP Annual Meeting
Functions Of Aminopeptidase N/CD13 In Vitro On Rheumatoid Arthritis Synovial Cells
Rachel Morgan¹, Nilofar Behbahani-Nejad², Judith Endres³ and David A. Fox⁴, ¹Immunology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Rheumatology/Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Aminopeptidase N (CD13, EC 3.4.11.2) is a metalloproteinase expressed on the surface of fibroblast like synoviocytes (FLS) that is also found in soluble form…
Abstract Number: 1854 • 2013 ACR/ARHP Annual Meeting
The Involvement Of Mast Cells In The Development Of Lung Fibrosis Via Modulating Pulmonary Fibroblast Immune Function
Shinjiro Kaieda¹, Morihisa Tajiri², Masaki Okamoto³, Naomi Yoshida⁴, Hiroaki Ida⁵, Tomoaki Hoshino⁴ and Takaaki Fukuda⁶, ¹Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, ²Department of Internal Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ³Department of Internal medicine, Division of respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁵Department of Internal Medicine, Division of REspirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁶Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan
Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown etiology; the most critical event in the evolution of fibrosis is the appearance…
Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 1857 • 2013 ACR/ARHP Annual Meeting
Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model
Wenfeng Tan¹, Xiaoke Feng², Lingxiao Xu³, Ke Gan⁴, Fang Wang³, Miaojia Zhang⁵, Hui Wu⁶ and Betty P. Tsao⁷, ¹Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ²Rheumatology, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China, ³Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, ⁴Rheumatology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ⁵Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁶Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁷Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA
Background/Purpose: We previously reported a RANKLpromoter SNP confers an elevated promoter activity after stimulation via binding to a SOX family transcription factor SOX5 and is…
Abstract Number: 1858 • 2013 ACR/ARHP Annual Meeting
Investigating The Role Of IL-22 In The Pathogenesis Of Familial Mediterranean FEVER
Dilek Keskin¹, Goksal Keskin², Ali Inal³ and Lale Ozisik⁴, ¹Immunology, DYB Research and Training Hospital, Ankara, Turkey, ²Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³GATA, Immunology, MD, Ankara, Turkey, ⁴Internal Medicine, MD, Ankara, Turkey
Background/Purpose: Familial mediterranean fever (FMF) is a familial disease characterized by recurrent episodes of febrile serositis, peritonitis, arthritis andpleuritis. Many studies have been performed as an attempt to understand…
Abstract Number: 1859 • 2013 ACR/ARHP Annual Meeting
OX40⁺ T Cells and OX40L⁺ B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity
Julie Kristine Laustsen¹, Tue Rasmussen², Malene Hvid³ and Bent Deleuran⁴, ¹Department of Medical Biomedicine, Aarhus University, Aarhus N, Denmark, ²Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies and autoreactive T cells, leading to synovitis and joint destruction. The…
Abstract Number: 1860 • 2013 ACR/ARHP Annual Meeting
Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With Cutaneous Lupus
Ming-Lin Liu^1,2,3, Muhammad Bashir^1,4, Meena Sharma^1,4, Honghui Xu^1,4, Kevin Williams³, Cynthia O. Anyanwu^4,5, Joyce Okawa^1,6 and Victoria P. Werth^1,4, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology,, Philadelphia V.A. Hospital, Philadelphia, PA, ³Department of Medicine, Temple University School of Medicine, Philadelphia, PA, ⁴Department of Dermatology, Philadelphia V.A. Hospital, Philadelphia, PA, ⁵Department of Dermatology, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ⁶Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) refers to variants of lupus erythematosus (LE) with exclusively or predominantly skin manifestations. CLE is associated with accumulation of autoantibodies…
Abstract Number: 1861 • 2013 ACR/ARHP Annual Meeting
Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis
Kim Heang Ly^1,2, Alexis Régent³, Elsa Molina⁴, Sofiane Saada⁴, Philippe Sindou⁴, Claire Le Jeunne⁵, Antoine Brezin⁶, Veronique witko-Sarsat³, Philippe Bertin⁷, Francois Labrousse⁸, Pierre-Yves Robert⁹, Anne-Laure Fauchais¹⁰, Elisabeth Vidal¹⁰, Luc Mouthon¹¹ and Marie-Odile Jauberteau⁴, ¹CHU Dupuytren, Limoges, Limoges, France, ²Immunology Laboratory, EA3842, Limoges Medical school, Limoges, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Immunology Laboratory, EA 3842, Limoges Medical School, Limoges, France, ⁵Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ⁶Service d’ophtalmologie, hôpital Cochin, AP-HP, Paris, France, ⁷Hôpital Dupuytren, Limoges, France, ⁸Department of Pathology, Limoges University Hospital, Limoges, France, ⁹Departement of Ophthalmology, Limoges University Hospital, Limoges, France, ¹⁰Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessels vasculitis. Hhistopathological findings show cellular infiltrates, internal elastic lumina disruption and intimal hyperplasia leading to luminal stenosis.…
Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Antonio da Silva¹, Ulrich Kronthaler¹, Cornelius Fritsch², Johann Poetzl³, Adelheid Rohde⁴, Anastassia Papandrikopoulou⁵, Hans-Peter Hofmann⁶ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, ³Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, ⁴Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, ⁵Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ⁶Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
Abstract Number: 1864 • 2013 ACR/ARHP Annual Meeting
Immunologic Markers and Molecular Mechanisms Associated With Increased Systemic Lupus Erythematosus Activity In Patients Not Taking Immunosuppressive Medications
Mikhail G. Dozmorov¹, Cory Giles², Krista M. Bean², Nicolas Dominguez², Jonathan D. Wren³, Joan T. Merrill⁴, Judith A. James⁵ and Joel M. Guthridge², ¹Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The course of systemic lupus erythematosus (SLE) is characterized by exacerbations (or flares) and remissions of disease activity. Predicting which patients are likely to…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].